Canada’s Drug Agency reversed course on lecanemab in roughly five months, flipping from a February 2026 recommendation against public reimbursement to a final positive recommendation issued September 1 — and that reversal now puts Eisai and BioArctic in front of a potential patient population the Alzheimer Society of Canada projects will nearly double, from 770,000 people living with dementia today to 1.7 million by 2050. The speed and completeness of the about-face matters clinically: CDA-AMC’s initial draft in February was a flat rejection despite Health Canada having approved lecanemab in October 2025, making this reconsideration outcome a meaningful regulatory correction rather than a routine step forward.
The positive recommendation is not reimbursement. Lecanemab must still pass through pan-Canadian Pharmaceutical Alliance price negotiations before individual provincial and territorial public drug plans make their own coverage decisions, a process that routinely takes a year or longer and often produces uneven access across Canada’s fragmented payer landscape. Patients with mild cognitive impairment or mild dementia due to Alzheimer’s disease — the eligible population named in the recommendation — are the ones who benefit from early intervention, so every month of negotiation delay translates directly into disease progression for people at the precise window where the drug has shown effect.
The global context sharpens the stakes. Lecanemab is now approved in 53 countries, and the FDA approved a subcutaneous autoinjector formulation in July 2026 that allows patients or caregivers to administer the drug at home, a delivery shift that could substantially reduce the infusion-center burden that has constrained real-world uptake elsewhere. Canada’s reimbursement pathway currently points only toward the intravenous formulation, which means the administration complexity that has slowed patient access in other markets will remain a live friction point during negotiations. The AHEAD 3-45 Phase 3 study in preclinical Alzheimer’s, fully recruited as of October 2024, also looms: a positive readout there would expand the eligible population well beyond what today’s recommendation covers, giving payers reason to negotiate hard on price now.
The single variable to track is the pace and geographic breadth of provincial coverage decisions once pan-Canadian negotiations conclude: whether large provinces like Ontario and Quebec move in lockstep or fragment into a patchwork will determine whether Canada’s positive recommendation translates into meaningful population-level access or remains a regulatory milestone without clinical reach.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
